Table 2.
Clinical findings and treatment: initial visit versus most recent follow-up.
| Initial visit | Follow up | P value | ||
|---|---|---|---|---|
| GDMT | Beta blocker | 58 (95) | 61 (100) | 0.248 |
| ACE I | 34 (55) | 9 (15) | <0.001 | |
| ARB | 11 (18) | 4 (7) | 0.070 | |
| ARNI | 8 (13) | 47 (77) | <0.001 | |
| ACE I/ARB/ARNI | 53 (86) | 60 (98) | 0.046 | |
| Aldactone | 34 (56) | 38 (63) | 0.009 | |
| Imdur | 2 (3) | 2 (3) | 1.000 | |
| Hydralazine | 2 (3) | 4 (7) | 0.480 | |
| Total number of GDMT | 2.31 ± 0.76 | 2.74 ± 0.66 | <0.001 | |
| Target GDMT doses | 0.54 ± 0.79 | 1.52 ± 1.10 | <0.001 | |
| NYHA class | I | 2 | 4 | 0.528 |
| II | 23 | 27 | ||
| III | 34 | 26 | ||
| IV | 2 | 1 | ||
| Ejection fraction (%) | 21.8 ± 7.8 | 36.2 ± 14.3 | <0.001 | |
| Hemodynamics | Heart rate | 75 ± 12 | 76 ± 11 | 0.965 |
| Systolic BP | 117 ± 15 | 115 ± 14 | 0.179 | |
| Diastolic BP | 70 ± 10 | 68 ± 10 | 0.388 | |
| Biochemistry | Sodium | 137 ± 2.6 | 138 ± 1.8 | 0.032 |
| Chloride | 101.97 ± 3.95 | 102.84 ± 3.30 | 0.011 | |
| Potassium | 4.2 ± 0.4 | 4.3 ± 0.3 | 0.378 | |
| Creatinine | 1.1 ± 0.4 | 1.1 ± 0.4 | 0.937 | |
| Hospitalizations (1 year before and after initial Encounter) | Heart failure | 26 | 8 | <0.001 |
| Renal failure | 0 | 3 | 0.902 | |
| ICD shock | 2 | 2 | 0.178 | |
| Death | 0 | 3 | NA |
Bold lettering indicates significant p values.